ASCO 2024 | Long-term efficacy of nivolumab combinations in advanced ESCC in CheckMate 648

Ian Chau, MD, Royal Marsden Hospital, London, UK, discusses the 45-month follow-up results of the Phase III CheckMate 648 study (NCT03143153) evaluating nivolumab with chemotherapy or ipilimumab in patients with advanced esophageal squamous cell carcinoma (ESCC) in the first-line setting. Both combinations demonstrated sustained overall survival (OS) benefits and durable responses compared to chemo alone, with improved duration of response. Safety profiles remained consistent, with no new adverse events. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.